ClinicalTrials.gov
public full text
Public Domain
A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis#862201
- HPP737 in Adult Patients With Plaque Psoriasis#846231
- Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis#800198
- Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765#1173637
- Systematic Review And Meta-Analysis Of Psoriasis Treatments.#826748
Record · ID 847970
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive